Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Sequence 1: FP, SFC, Placebo	Fluticasone Propionate (FP) 100 micrograms (mcg) twice daily (BID) in the first treatment period: Salmeterol/Fluticasone Propionate Combination (SFC) 50/100 mcg BID in the second treatment period: Placebo in the third treatment period
Sequence 2: Placebo, SFC, FP	Placebo in the first treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the second treatment period: Flutucasone Propionate 100 mcg BID in the third treatment period
Sequence 3: SFC, FP, Placebo	Salmeterol/Fluticasone Propionate 50/100 Combination mcg BID in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Placebo in the third treatment period
Sequence 4: SFC, Placebo, FP	Salmeterol/Fluticasone Priopionate Combination 50/100 mcg BID in the first treatment period: Placebo in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
Sequence 5: FP, Placebo, SFC	Fluticasone Propionate 100 mcg BID in the first treatment period: Placebo in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
Sequence 6: Placebo, FP, SFC	Placebo in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Salmeterol/Fluticasone Priopionate Combination 50/100 mcg BID in the third treatment period

Participant Flow for 3 periods

	Sequence 1: FP, SFC, Placebo	Sequence 2: Placebo, SFC, FP	Sequence 3: SFC, FP, Placebo	Sequence 4: SFC, Placebo, FP	Sequence 5: FP, Placebo, SFC	Sequence 6: Placebo, FP, SFC
STARTED	4	4	4	3	4	4
COMPLETED	4	4	4	3	4	4
NOT COMPLETED	0	0	0	0	0	0

	Sequence 1: FP, SFC, Placebo	Sequence 2: Placebo, SFC, FP	Sequence 3: SFC, FP, Placebo	Sequence 4: SFC, Placebo, FP	Sequence 5: FP, Placebo, SFC	Sequence 6: Placebo, FP, SFC
STARTED	4	4	4	3	4	4
COMPLETED	4	4	4	3	3	4
NOT COMPLETED	0	0	0	0	1	0
Withdrawal by Subject	0	0	0	0	1	0

	Sequence 1: FP, SFC, Placebo	Sequence 2: Placebo, SFC, FP	Sequence 3: SFC, FP, Placebo	Sequence 4: SFC, Placebo, FP	Sequence 5: FP, Placebo, SFC	Sequence 6: Placebo, FP, SFC
STARTED	4	4	4	3	3	4
COMPLETED	4	4	4	3	3	4
NOT COMPLETED	0	0	0	0	0	0

Reporting Groups

	Description
Overall Study Population	Overall Study Population: participants in all three treatment periods

Baseline Measures

	Overall Study Population
Number of Participants   [units: participants]	23
Age   [units: years] Mean ± Standard Deviation	36.6 ± 6.63
Gender   [units: participants]
Female	9
Male	14
Race/Ethnicity, Customized   [units: participants]
African American	2
Caucasion	21

1.  Primary:

Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-allergen Challenge on Day 35   [ 0-6 hours post allergen challenge, 10-11 hours post treatment, Day 35 ]

2.  Secondary:

Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post Allergen Challenge on Day 14   [ 0-6 hours, post allergen challenge, 1 hour post treatment, Day 14 ]